Aspire Biopharma Holdings, Inc.
ASBPNasdaq
$6.24
↓ -0.6%Jul 17 close · end-of-day
Price
1Y↓ -98.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$977,714.40
Enterprise Value
-$4.9M
P/E
—
P/S
—
P/B
0.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$11.8M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-304.1%
ROIC
—
Debt / Equity
—
Net Cash
$5.9M
Return 1Y
-98.5%
Company profile
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.
- CEO
- Kraig T. Higginson
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- New York
- Website
- aspirebiolabs.com
Earnings
ASBP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$28,353.00—
Diluted EPS-$20.57↓ -95.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | $6,202.00 |
| Gross profit | — | — | — | -$116.00 |
| Operating income | — | — | -$1.2M | -$19.4M |
| Net income | $3.3M | $4.5M | -$1.3M | -$24.5M |
| Diluted EPS | — | — | -$1.90 | -$16.38 |
| Operating cash flow | -$1.4M | -$653,107.00 | -$265,186.00 | -$4.9M |
| Free cash flow | — | — | — | — |
| Gross margin | — | — | — | -1.9% |
| Operating margin | — | — | — | -312016.9% |
| Net margin | — | — | — | -394725.1% |
| Line item | Q3 '24 | Q3 '24 | Q3 '24 | Q1 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $1,941.00 | — | $28,353.00 |
| Gross profit | — | — | — | — | — | $884.00 | — | $5,750.00 |
| Operating income | — | -$215,256.00 | — | -$15.6M | — | -$1.1M | — | -$1.6M |
| Net income | -$96,923.00 | -$216,269.00 | -$765,710.00 | -$15.9M | -$2.0M | -$1.9M | -$4.7M | -$3.2M |
| Diluted EPS | — | -$0.01 | — | -$504.88 | — | -$0.04 | — | -$20.57 |
| Operating cash flow | -$56,244.00 | -$495,540.00 | $479,569.00 | -$1.8M | -$1.1M | -$1.1M | -$927,841.00 | -$3.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | 45.5% | — | 20.3% |
| Operating margin | — | — | — | — | — | -59015.8% | — | -5806.0% |
| Net margin | — | — | — | — | — | -95337.1% | — | -11367.0% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.